Med. Pro Praxi 2009; 6(3): 140-143

Oral antidiabetics in type 2 DM treatment

MUDr. Milan Flekač, Ph.D
III. interní klinika VFN a 1. LF UK, Praha

Type 2 diabetes mellitus (T2D) is chronic disease with progressive character, characterised by relative insufficiency of insulin, leading to the

inadequate utilization of glucose manifesting with hyperglycaemia. Therapy of patients with T2D is global and includes therapy of

arterial hypertension, hyperlipoproteinaemia, obesity and another symptoms of metabolic syndrome. There is a variety of oral antidiabetic

agents for use to this time, affecting insulin secretion and/or insulin resistance. Pharmacological therapy has to be started at the

same time of clinical diagnosis.

Keywords: diabetes mellitus, oral antidiabetic agents, therapy.

Published: June 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Flekač M, D P. Oral antidiabetics in type 2 DM treatment. Med. praxi. 2009;6(3):140-143.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Standardy ČDS. Laboratorní diagnostika a sledování stavu diabetu mellitu, 2005, www.diab.cz/modules/standardy.
    2. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006; 49: 1711-1721. Go to original source... Go to PubMed...
    3. Perušičová J, Kvapil M. Postprandiální glykemie. Praha: Triton, 2006.
    4. IDF clinical guidelines task force. Global guidelines for type 2 diabetes: recommendation for standard, comprehensive and minimal care. Diabet Med 2006; 23: 579-593. Go to PubMed...
    5. Perušičová J. Perorální antidiabetika-současnost. Interni Med. 2008; 10(1): 15-18.
    6. Selvin E, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168(19): 2070-2080. Go to original source... Go to PubMed...
    7. Korytkowski MT. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. Pharmacotherapy 2004; 24: 606-620. Go to original source... Go to PubMed...
    8. Martens FM, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62(10): 1463-1480. Go to original source... Go to PubMed...
    9. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001; 61: 1625-1660. Go to original source... Go to PubMed...
    10. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in diabetes 2 type: A systematic review and meta-analysis. JAMA 2007; 298: 194-206. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.